Page last updated: 2024-12-05

cepharanthine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cepharanthine: isoquinoline alkaloid from tubers of STEPHANIA; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cepharanthine : A bisbenzylisoquinoline alkaloid from tubers of Stephania; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10206
CHEMBL ID449782
CHEBI ID3546
SCHEMBL ID154545
MeSH IDM0049803

Synonyms (85)

Synonym
AC-15206
NSC623442 ,
nsc-623442
(+)-cepharanthine
cepharanthin
o-methylcepharanoline
oxyacanthan, 6',12'-dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))-
cepharantin
SDCCGMLS-0066893.P001
cepharanthine [jan]
6',12'-dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))oxyacanthan
nsc 623442
brn 0075231
ccris 6539
BSPBIO_003563
UPCMLD-DP054:001
C09391
481-49-2
cepharanthine
smr000445632
MLS000728518
UPCMLD-DP054
cepharanthine (tn)
cepharanthine (jan)
D01035
NCGC00095194-01
NCGC00161621-01
KBIO3_002909
SPECTRUM3_001963
SPECTRUM2_000832
SPBIO_000783
SPECTRUM1505322
NCGC00161621-02
HMS1922J12
CHEMBL449782
chebi:3546 ,
STK801907
(14s,27r)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.2~16,19~.1~3,10~.1~21,25~.0~4,8~.0~14,39~.0~31,35~]nonatriaconta-1(33),3,8,10(39),16,18,21(36),22,24,31,34,37-dod
ecaene (non-preferred name)
AKOS004119865
dtxcid4025957
dtxsid6045957 ,
tox21_111483
cas-481-49-2
nsc758965
pharmakon1600-01505322
nsc-758965
HMS2232F21
S4238
CCG-40294
7592yj0j6t ,
4-27-00-09061 (beilstein handbook reference)
unii-7592yj0j6t
cepharanthine [mi]
cepharanthine [who-dd]
bdbm50423643
BBL030154
SCHEMBL154545
NCGC00161621-03
tox21_111483_1
(14s,27r)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.2(16,19).1(3,10).1(21,25).0(4,8).0(14,39).0(31,35)]nonatriaconta-1(33),3,8,10(39),16,18,21(36),22,24,31,34,37-dodecaene
Q-100524
AB00643356_08
AB00643356_09
SR-01000779734-4
sr-01000779734
SR-01000779734-3
(14s,27r)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.2??,??.1?,??.1??,??.0?,?.0??,??.0??,??]nonatriaconta-1(33),3,8,10(39),16,18,21(36),22,24,31,34,37-dodecaene
cepharanthine, >=98% (hplc)
cepharanthine, >=95% (hplc)
SBI-0207049.P001
NCGC00161621-05
HY-N6972
mfcd00210482
cepharanthin,(s)
12-o-methylcepharanoline
AS-17451
Q15410888
BRD-K96194081-001-06-0
(14s,27r)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.216,19.13,10.121,25.04,8.031,35.014,39]nonatriaconta-1(33),3(39),4(8),9,16(38),17,19(37),21,23,25(36),31,34-dodecaene
NCGC00161621-13
CS-0007138
A871948
22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.216,19.13,10.121,25.04,8.031,35.014,39]nonatriaconta-1(33),3(39),4(8),9,16(38),17,19(37),21,23,25(36),31,34-dodecaene
M2968

Research Excerpts

Overview

Cepharanthine (CEP) is a natural biscoclaurine alkaloid of plant origin. It was recently demonstrated to have anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activity. Cepharant is a potential candidate for treatment of cerebral ischemia/reperfusion (I/R) injury.

ExcerptReferenceRelevance
"Cepharanthine (CEP) is an alkaloid extracted from Stephania cepharantha Hayata. "( Cepharanthine Regulates Autophagy via Activating the p38 Signaling Pathway in Lung Adenocarcinoma Cells.
Li, G; Qiao, K; Wang, C; Xu, X, 2022
)
3.61
"Cepharanthine (CEP) is a natural biscoclaurine alkaloid of plant origin and was recently demonstrated to have anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activity. "( Evaluating cepharanthine analogues as natural drugs against SARS-CoV-2.
Hijikata, A; Hirokawa, T; Kanaya, S; Nakae, S; Nakajima, S; Ota, M; Shionyu, M; Shionyu-Mitsuyama, C; Shirai, T; Watashi, K, 2022
)
2.55
"Cepharanthine (CEP) is an active alkaloid isolated from Stephania Cepharantha Hayata. "( Cepharanthine ameliorates dextran sulphate sodium-induced colitis through modulating gut microbiota.
He, L; Wang, HG; Wen, X; Yang, XZ; Zhang, JL; Zhang, MH; Zhang, MN, 2022
)
3.61
"Cepharanthine is an active ingredient separated and extracted from "( Pharmacological Effects and Clinical Prospects of Cepharanthine.
Dou, G; Du, L; Li, Q; Liang, D, 2022
)
2.42
"Cepharanthine (CEP) is a bisbenzylisoquinoline alkaloid compound found in plants of the Stephania genus, which has biological functions such as regulating autophagy, inhibiting inflammation, oxidative stress, and apoptosis. "( Research progress on pharmacological effects and mechanisms of cepharanthine and its derivatives.
Chen, Y; Li, Y; Liu, Z; Shi, L; Wang, J; Wang, S; Wei, B; Zhang, L; Zhang, S; Zhao, S, 2023
)
2.59
"Cepharanthine (CEP) is a drug candidate for tumor, viral infection, and some inflammatory diseases, but its effect on rheumatoid arthritis (RA) and the underlying mechanism are incompletely understood."( Herbal compound cepharanthine attenuates inflammatory arthritis by blocking macrophage M1 polarization.
Cheng, RJ; Fox, DA; Hu, Y; Li, S; Liu, Y; Lu, C; Luo, Y; Pu, Y; Tang, Z; Tsou, PS; Wei, S; Wen, J; Wu, L; Zhang, Q; Zhong, Y, 2023
)
2.7
"Cepharanthine (CEP) is a potential candidate for treatment of cerebral ischemia/reperfusion (I/R) injury, due to its anti-inflammatory and anti-oxidative properties. "( Cepharanthine attenuates cerebral ischemia/reperfusion injury by reducing NLRP3 inflammasome-induced inflammation and oxidative stress via inhibiting 12/15-LOX signaling.
Han, F; Liang, Q; Liang, S; Piao, X; Shao, S; Wu, Y; Zhao, D; Zhao, J, 2020
)
3.44
"Cepharanthine (CEP) is a naturally occurring alkaloid derived from Stephania cepharantha Hayata and demonstrated to have unique anti-inflammatory, antioxidative, immunomodulating, antiparasitic, and antiviral properties. "( Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19.
Koman, I; Okediji, P; Rogosnitzky, M, 2020
)
3.44
"Cepharanthine (CEP) is a biscoclaurine alkaloid extracted from Stephania cepharantha and has been shown to have an anti-tumour effect on different types of cancers. "( Cepharanthine Induces Autophagy, Apoptosis and Cell Cycle Arrest in Breast Cancer Cells.
Ding, X; Gao, S; Li, X; Qi, W; Yang, Q, 2017
)
3.34
"Cepharanthine (CEP) is a natural plant alkaloid, and has anti-inflammatory, antineoplastic, antioxidative and anticancer properties. "( Cepharanthine Enhances TRAIL-Mediated Apoptosis Through STAMBPL1-Mediated Downregulation of Survivin Expression in Renal Carcinoma Cells.
Kwon, TK; Min, KJ; Seo, SU; Shahriyar, SA; Woo, SM, 2018
)
3.37
"Cepharanthine (CEP) is a drug used in Japan since the 1950s to treat a number of acute and chronic diseases, including treatment of leukopenia, snake bites, xerostomia and alopecia. "( Cepharanthine: An update of its mode of action, pharmacological properties and medical applications.
Bailly, C, 2019
)
3.4
"Cepharanthine is a biscoclaurine alkaloid extracted from Stephania cepharantha that has a variety of biological activities in multiple diseases. "( Cepharanthine hydrochloride degrades polyglutamine-expanded androgen receptor proteins through an autophagy pathway in neuron cells.
Fan, J; Huang, Z; Su, G; Wang, Y, 2019
)
3.4
"Cepharanthine (CEP) is an alkaloid isolated from this plant with potential innovative antiplasmodial activity."( In vitro and in vivo combination of cepharanthine with anti-malarial drugs.
Chapus, C; Desgrouas, C; Dormoi, J; Ollivier, E; Parzy, D; Taudon, N, 2014
)
1.4
"Cepharanthine is a medicinal plant-derived natural compound which possesses potent anti-cancer properties. "( Cepharanthine induces apoptosis through reactive oxygen species and mitochondrial dysfunction in human non-small-cell lung cancer cells.
Cui, R; Hua, P; Li, X; Sun, M; Tian, X; Zhang, G; Zhang, X; Zhang, Y, 2015
)
3.3
"Cepharanthine (CEP) is a biscoclaurine amphipathic alkaloid isolated from the plant Stephania cepharantha Hayata. "( Cepharanthine induces apoptosis through the mitochondria/caspase pathway in murine dendritic cells.
Baba, M; Toyama, M; Uto, T; Yoshinaga, K, 2016
)
3.32
"Cepharanthine is a biscoclaurine alkaloid extracted from Stephania cepharantha Hayata, which is widely used for the treatment of many acute and chronic diseases, and can exert antitumor effects on several human cancer cells."( Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Ferdous, T; Harada, K; Itashiki, Y; Mano, T; Mori, Y; Takii, M; Ueyama, Y, 2009
)
1.46
"Cepharanthine is a biscoclaurine alkaloid extracted from Stephania cepharantha Hayata, which is widely used for the treatment of many acute and chronic diseases, and can exert antitumor effects on several human cancer cell lines. "( Cepharanthine inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing expression of vascular endothelial growth factor and interleukin-8.
Ferdous, T; Harada, K; Itashiki, Y; Mano, T; Mori, Y; Takii, M; Ueyama, Y, 2009
)
3.24
"Cepharanthine (CE) is a plant alkaloid that possesses bioactive properties, with various known actions."( Cepharanthine exerts anti-inflammatory effects via NF-κB inhibition in a LPS-induced rat model of systemic inflammation.
Hagiwara, S; Hasegawa, A; Koga, H; Kudo, K; Kusaka, J; Noguchi, T, 2011
)
2.53
"Cepharanthine (CEP) is a naturally occurring alkaloid extracted from the plant Stephania cepharantha Hayata. "( Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions.
Danks, R; Rogosnitzky, M, 2011
)
2.06
"Cepharanthine is a biscoclaurine alkaloid extracted from Stephania cepharantha Hayata. "( Cepharanthine exerts antitumor activity on oral squamous cell carcinoma cell lines by induction of p27Kip1.
Harada, K; Kawaguchi, S; Sato, M; Yamamoto, S; Yoshida, H,
)
3.02
"Cepharanthine (Ce) is a biscoclaurine alkaloid extracted from Stephania cepharantha Hayata. "( Cepharanthine enhances in vitro and in vivo thermosensitivity of a mouse fibrosarcoma, FSa-II, based on increased apoptosis.
Akaki, S; Asaumi, J; Dendo, S; Gao, XS; Himei, K; Hiraki, Y; Joja, I; Kanazawa, S; Kato, H; Kawasaki, S; Kuroda, M; Okumura, Y; Shibuya, K; Wang, Y, 2004
)
3.21
"Cepharanthine is a plant alkaloid that effectively reverses resistance to anticancer agents."( Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells.
Akiyama, S; Che, XF; Furukawa, T; Haraguchi, M; Ikeda, R; Jeung, HC; Nakamura, K; Okumura, H; Shibayama, Y; Sumizawa, T; Takeda, Y; Ushiyama, M; Yamada, K; Yamaguchi, T; Zheng, CL, 2005
)
2.49
"Cepharanthine is a biscoclaurine alkaloid isolated from Stephania cepharantha Hayata and has been shown to have antiinflammatory, antiallergic, and immunomodulatory activities in vivo. "( Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells.
Baba, M; Okamoto, M; Ono, M, 1998
)
1.97
"Cepharanthine (CEP) is a known membrane stabilizer that has been widely used in Japan for the treatment of several disorders such as anticancer therapy-provoked leukopenia. "( Cepharanthine activates caspases and induces apoptosis in Jurkat and K562 human leukemia cell lines.
Akhand, AA; Hayakawa, A; Hossain, K; Kato, M; Kurosawa, M; Liu, W; Nakashima, I; Suzuki, H; Takeuchi, K; Wu, J; Yoshihara, M; Zhou, YW, 2001
)
3.2
"Cepharanthine is a biscoclaurine alkaloid isolated from Stephania cepharantha Hayata and has been shown to have anti-inflammatory, anti-allergic, and immunomodulatory activities in vivo."( Suppression of cytokine production and neural cell death by the anti-inflammatory alkaloid cepharanthine: a potential agent against HIV-1 encephalopathy.
Baba, M; Okamoto, M; Ono, M, 2001
)
1.25
"Cepharanthine is a biscoclaurine alkaloid that primarily inhibits phospholipase A2."( Cepharanthine (biscoclaurine alkaloid) treatment in endotoxic shock of suckling rats.
Goto, M; Hurley, RM; Zeller, WP, 1991
)
2.45
"Cepharanthine is a biscoclaurin type alkaloid, crude drug, and its main efficacy is to stabilize cell membranes."( [Therapeutic effects of cepharanthine on the experimental otitis media with effusion].
Hori, F; Kawauchi, H; Mogi, G, 1989
)
1.31

Effects

Cepharanthine (CEP) has been shown to circumvent multidrug resistance in P-glycoprotein-expressing cell lines. It has excellent anti-SARS-CoV-2 properties, indicating its favorable potential for COVID-19 treatment.

ExcerptReferenceRelevance
"Cepharanthine (CEP) has excellent anti-SARS-CoV-2 properties, indicating its favorable potential for COVID-19 treatment. "( Bioavailability Enhancement of Cepharanthine via Pulmonary Administration in Rats and Its Therapeutic Potential for Pulmonary Fibrosis Associated with COVID-19 Infection.
Chen, G; Dou, G; Gan, H; Gu, R; Han, P; Li, J; Liu, T; Meng, Z; Wang, F; Wu, Z; Zhu, X, 2022
)
2.45
"Cepharanthine has also been reported to have numerous pharmacological effects besides the inhibition of P-gp."( Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells.
Akiyama, S; Che, XF; Furukawa, T; Haraguchi, M; Ikeda, R; Jeung, HC; Nakamura, K; Okumura, H; Shibayama, Y; Sumizawa, T; Takeda, Y; Ushiyama, M; Yamada, K; Yamaguchi, T; Zheng, CL, 2005
)
2.49
"Cepharanthine has been reported to have several clinical effects, such as enhancement of the immune response, improvement of peripheral circulation, vasodilation and inhibition of platelet aggregation, all of which may also be beneficial to sickle-cell patients."( In vitro anti-sickling effect on cepharanthine.
Ohnishi, ST; Sato, T, 1982
)
1.27
"Cepharanthine (CEP) has been shown to circumvent multidrug resistance in P-glycoprotein-expressing cell lines."( Modulation of multidrug resistance by cepharanthine in fresh human gastrointestinal tumor cells.
Arii, K; Hotta, T; Iwahashi, M; Mizobata, S; Noguchi, K; Tamai, M; Tani, M; Tanimura, H; Terasawa, H; Tsunoda, T; Yamaue, H,
)
1.12

Actions

Cepharanthine did not suppress body weight gain nor did it delay death as seen with glucocorticoid treatment. It was found to suppress HIV-1 LTR-driven gene expression through the inhibition of NF-kappaB activation.

ExcerptReferenceRelevance
"Cepharanthine was found to suppress HIV-1 LTR-driven gene expression through the inhibition of NF-kappaB activation."( Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells.
Baba, M; Okamoto, M; Ono, M, 1998
)
1.25
"Cepharanthine did not suppress body weight gain nor did it delay death as seen with glucocorticoid treatment."( Cepharanthine (biscoclaurine alkaloid) treatment in endotoxic shock of suckling rats.
Goto, M; Hurley, RM; Zeller, WP, 1991
)
2.45
"Cepharanthine did not increase plasma corticosterone level in rats in the state of dexamethasone suppression of the pituitary-adrenocortical system, in which the level was lowered."( [Stimulation of pituitary-adrenocortical system by cepharanthine].
Akasu, M; Inoue, H; Seyama, Y; Yamashita, S; Yoshikawa, N, 1986
)
1.24
"Cepharanthine was known to inhibit histamine release from mast cells obtained from sensitized animals."( [Mode of the anti-allergic action of cepharanthine on an experimental model of allergic rhinitis].
Akasu, M; Inoue, H; Kohno, H; Seyama, Y; Yamashita, S, 1987
)
1.27

Treatment

Cepharanthine and IR treatment achieved maximum cytotoxic effects on HeLa cells with regard to apoptosis induction. Pretreatment with cepharAnthine (0.1-2 microM) suppressed the PDGF-stimulated increase in fibronectin in a dose-dependent manner.

ExcerptReferenceRelevance
"Cepharanthine and IR treatment achieved maximum cytotoxic effects on HeLa cells with regard to apoptosis induction."( Inhibition of signal transducer and activator of transcription 3 and cyclooxygenase-2 is involved in radiosensitization of cepharanthine in HeLa cells.
Chen, Z; Fang, ZH; Li, YJ; Wang, JJ; Zhu, LH, 2013
)
1.32
"The cepharanthine treatment results in a significant suppression of tumor growth."( Cepharanthine exerts antitumor activity on oral squamous cell carcinoma cell lines by induction of p27Kip1.
Harada, K; Kawaguchi, S; Sato, M; Yamamoto, S; Yoshida, H,
)
2.05
"Pretreatment with cepharanthine (0.1-2 microM) suppressed the PDGF-stimulated increase in fibronectin in a dose-dependent manner."( Inhibitory effect of cepharanthine on fibronectin production in growth factor-stimulated rat mesangial cells.
Akiba, S; Hayama, M; Inoue, R; Sato, T, 2000
)
0.95
"The treatment with cepharanthine potentiated these blocking effects induced by doxorubicin in cells."( [Assay of flow cytometry for the effect of cepharanthine on resistance to doxorubicin].
Furusawa, S; Hayashi, A; Kisara, S; Maekawa, I; Sasaki, K; Takayanagi, Y, 1992
)
0.87

Toxicity

ExcerptReferenceRelevance
" Cepharanthine, which had no toxic action on survival, increased intracellular ADR uptake by about 20% for 1 h incubation at 37 degrees C, and increased cellular ADR retention after incubation in an ADR-free medium for 4 h from 15% to 75%."( Modification of cellular efflux and cytotoxicity of adriamycin by biscoclaulin alkaloid in vitro.
Karino, Y; Kawasaki, S; Nagaoka, S; Nakanishi, T; Sasaki, K, 1987
)
1.18
" The data suggest that the combination of these two drugs, that individually express a low toxic profile, may have strong antitumor potential."( Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines.
Ardelt, B; Darzynkiewicz, Z; Halicka, HD; Ita, M; Kurose, A; Shogen, K; Tanaka, T, 2008
)
0.59
" Secondary outcomes are changes in the longest diameter of the target lesion from baseline to weeks 4 and 8, improvement and deterioration rates according to appearance and severity criteria at weeks 4 and 8, change in pain intensity when drinking room-temperature water from baseline to week 4, changes in pain intensity at rest from baseline to weeks 4 and 8, and the rates of adverse events."( Cepharanthine and Oral Lichen Planus Efficacy (COLE) study: protocol for a multicentre randomised controlled study assessing the efficacy and safety of cepharanthine with topical corticosteroids in oral lichen planus.
Isogawa, M; Kasahara, M; Kirita, T; Matsusue, Y; Sugiura, T; Yagyuu, T; Yamamoto, K, 2023
)
2.35

Compound-Compound Interactions

The anticancer effect of a podophyllotoxin derivative, etoposide (ETOP), on the colony forming efficiency (CFE) of B16 melanoma cells was studied. The CFE inhibition by the combination with a biscoclaurine alkaloid, Cepharanthine (Ceph) was studied in vitro.

ExcerptReferenceRelevance
"The anticancer effect of a podophyllotoxin derivative, etoposide (ETOP), and the vinca alkaloids, vincristine (VCR) and vindesine (VDS), on the colony forming efficiency (CFE) of B16 melanoma cells, and the CFE inhibition by the combination with a biscoclaurine alkaloid, Cepharanthine (Ceph) were studied in vitro."( [Enhancement of the effects of anticancer agents on B16 melanoma cells by combination with cepharanthine--I. Alkaloids].
Kubota, K; Kubota, R; Yamada, S, 1992
)
0.68
" Hydroxyurea, antimetabolite, showed a time-dependent inhibition of CFE, and the combination with Ceph enhanced CFE inhibition by 29%, which is stable and independent of the treatment time."( [Enhancement of the effects of anticancer agents on B16 melanoma cells by combination with cepharanthine--II. Antimetabolite, alkylating agent, nitrosourea].
Kubota, K; Kubota, R; Yamada, S, 1992
)
0.5
"A 64-year-old man with iliac bone metastasis from left renal cell carcinoma was treated by intra-arterial infusion chemotherapy using vinblastine and epirubicine in combination with a biscoclaurine alkaloid, Cepharanthin."( Intra-arterial infusion chemotherapy in combination with a biscoclaurine alkaloid, Cepharanthin, to treat bone metastasis arising from renal cell carcinoma.
Arai, Y; Kakehi, Y; Kanba, T; Shichiri, Y; Yoshida, O; Yoshida, S, 1994
)
0.29
" Based on the results, we treated 6 patients with metastatic renal cell carcinomas (4: bones, 2: contralateral kidneys) by intraarterial injection of vinblastine and adriamycin (or epirubicin) in combination with cepharanthin."( [Intraarterial chemotherapy for metastatic renal cell carcinomas: combination with MDR-overcoming agents].
Arai, Y; Hiura, M; Kakehi, Y; Kanematsu, A; Segawa, T; Shichiri, Y; Yoshida, O, 1994
)
0.29
"In this study, the response of human OSCC cells to cepharanthine alone and in combination with S-1 was examined using nude mouse xenograft models."( Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Ferdous, T; Harada, K; Itashiki, Y; Mano, T; Mori, Y; Takii, M; Ueyama, Y, 2009
)
0.99
" In the present study, a network pharmacology-based approach combined with RNA-sequencing (RNA-seq), molecular docking, and molecular dynamics (MD) simulation was performed to determine hub targets and potential pharmacological mechanism of CEP against COVID-19."( Dissecting the molecular mechanism of cepharanthine against COVID-19, based on a network pharmacology strategy combined with RNA-sequencing analysis, molecular docking, and molecular dynamics simulation.
Fang, S; Li, W; Liu, J; Liu, S; Sun, T; Tan, S; Zeng, Y; Zhang, B, 2022
)
0.99

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The aim of this article was to design a self-emulsifying drug delivery system (SEDDS) of loaded cepharanthine (CEP) to improve the oral bioavailability in rats."( Preparation and Evaluation of Self-emulsifying Drug Delivery System (SEDDS) of Cepharanthine.
Cui, M; Gao, P; Jiang, Z; Luo, Q; Mu, C; Yang, X, 2021
)
1.07
"Niclosamide, a widely-used anthelmintic drug, inhibits SARS-CoV-2 virus entry through TMEM16F inhibition and replication through autophagy induction, but the relatively high cytotoxicity and poor oral bioavailability limited its application."( Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2.
Chang, SY; Chao, TL; Chou, YT; Jan, JT; Juang, YP; Liang, PH; Lin, RX; Ma, HH, 2022
)
0.72
" The present study aimed to improve the bioavailability of CEP by optimizing its solubility and through a pulmonary delivery method, which improved its bioavailability by five times when compared to that through the oral delivery method (68."( Bioavailability Enhancement of Cepharanthine via Pulmonary Administration in Rats and Its Therapeutic Potential for Pulmonary Fibrosis Associated with COVID-19 Infection.
Chen, G; Dou, G; Gan, H; Gu, R; Han, P; Li, J; Liu, T; Meng, Z; Wang, F; Wu, Z; Zhu, X, 2022
)
1.01

Dosage Studied

ExcerptRelevanceReference
" The fact that enhancement was 6-10 fold greater in resistant then in sensitive cells, as well as the loss of biphasic properties of adriamycin on dose-response curves after combined treatment, indicate that cepharanthine may play a role in overcoming drug resistance in some tumor cells."( Enhancement of adriamycin cytotoxicity in sensitive and resistant sublines of human tumor cells by calcium antagonists.
Mircheva, J; Tsuruo, T, 1990
)
0.47
" A concentration- or dose-response relationship was shown between the concentration and dose of CH and Rho123 accumulation or the antitumor activity."( Using rhodamine 123 accumulation in CD8 cells as a surrogate indicator to study the P-glycoprotein modulating effect of cepharanthine hydrochloride in vivo.
Cai-Hong, Z; Fang, M; Jin-Hua, J; Li, H; Ning, W; Qing-Duan, W; Xiao-Juan, G; Yan, Z, 2011
)
0.58
" High-dose CEP was well tolerated, and in some patients single-agent CEP therapy resulted in a significant elevation of platelets, allowing a reduced dosage of PSL."( [Clinical efficacy of high-dose cepharanthine for idiopathic thrombocytopenic purpura: retrospective multicenter analysis].
Endo, T; Fujimoto, K; Hashino, S; Imamura, M; Iwasaki, H; Kobayashi, N; Kohda, K; Kurosawa, M; Maekawa, I; Miyagishima, T; Miyake, T; Sasagawa, H; Takahata, M; Tanaka, J; Teshima, T; Tsustumi, Y, 2012
)
0.66
" However, there is no detailed research on its specific mechanism and dosage and administration methods, especially clinical research is limited."( Research progress on pharmacological effects and mechanisms of cepharanthine and its derivatives.
Chen, Y; Li, Y; Liu, Z; Shi, L; Wang, J; Wang, S; Wei, B; Zhang, L; Zhang, S; Zhao, S, 2023
)
1.15
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
bisbenzylisoquinoline alkaloidA type of benzylisoquinoline alkaloid whose structures are built up of two benzylisoquinoline units linked by ether bridges. Various structural patterns resulting from additional bridging between the two units by direct carbon-carbon bridging or by methylenedioxy groups are common.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (61)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency15.84890.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency25.11890.044717.8581100.0000AID485341
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency35.48130.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
Chain A, CruzipainTrypanosoma cruziPotency15.84890.002014.677939.8107AID1476
acetylcholinesteraseHomo sapiens (human)Potency29.22060.002541.796015,848.9004AID1347395; AID1347398
glp-1 receptor, partialHomo sapiens (human)Potency7.07950.01846.806014.1254AID624417
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency6.00703.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency4.89000.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency23.91450.173734.304761.8120AID1346859
Fumarate hydrataseHomo sapiens (human)Potency35.48130.00308.794948.0869AID1347053
SMAD family member 3Homo sapiens (human)Potency23.91450.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency14.93700.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency3.90770.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency0.08910.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency24.19550.000221.22318,912.5098AID1259243; AID1259247; AID743036; AID743063
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency19.95260.707912.194339.8107AID720542
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency26.72090.001022.650876.6163AID1224838; AID1224839; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency6.37700.01237.983543.2770AID1346984; AID1645841
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency5.31010.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency9.96600.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency25.72030.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency29.84700.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency18.81150.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.13170.000229.305416,493.5996AID1259244
GVesicular stomatitis virusPotency34.67130.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency17.37680.00108.379861.1304AID1645840
polyproteinZika virusPotency35.48130.00308.794948.0869AID1347053
glucocerebrosidaseHomo sapiens (human)Potency11.51890.01268.156944.6684AID2101
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency18.83710.001024.504861.6448AID743212; AID743215; AID743227
caspase-3Homo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
IDH1Homo sapiens (human)Potency16.36010.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency11.22020.035520.977089.1251AID504332
thyroid stimulating hormone receptorHomo sapiens (human)Potency25.15670.001628.015177.1139AID1259385; AID1259395
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency9.520519.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency3.23670.057821.109761.2679AID1159526; AID1159528
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency39.81070.10009.191631.6228AID1346983
Histone H2A.xCricetulus griseus (Chinese hamster)Potency55.19650.039147.5451146.8240AID1224845; AID1224896
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency3.98110.01262.451825.0177AID485313
chromobox protein homolog 1Homo sapiens (human)Potency28.18380.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency32.64270.00419.984825.9290AID504444
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency14.12540.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency10.39720.000323.4451159.6830AID743065; AID743067
flap endonuclease 1Homo sapiens (human)Potency28.18380.133725.412989.1251AID588795
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency14.21930.000627.21521,122.0200AID743202; AID743219
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency11.22020.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency5.84330.004611.374133.4983AID624296; AID624297
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency21.13170.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency36.01390.00339.158239.8107AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency34.67130.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency23.71010.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency21.13170.001551.739315,848.9004AID1259244
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency1.63710.009610.525035.4813AID1479145; AID1479148
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency34.67130.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency34.67130.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Trypanothione reductaseTrypanosoma cruziKi29.60000.07605.15297.6000AID343384; AID343397
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (168)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (50)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (145)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID745566Cytotoxicity against human ECA109 cells after 48 hrs by MTT assay2013Journal of natural products, May-24, Volume: 76, Issue:5
Cytotoxic bisbenzylisoquinoline alkaloids from Stephania epigaea.
AID1663397Inhibition of P-glycoprotein-mediated Rhodamine-123 efflux in human MOLT4/DNR cells assessed as inhibition of P-glycoprotein efflux function at 10 uM incubated for 1 hr by flow cytometry2020Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12
Bisbenzylisoquinoline alkaloids and P-glycoprotein function: A structure activity relationship study.
AID1769493Antiproliferative activity against human MDA-MB-231 assessed as cell growth inhibition after 48 hrs by SRB assay
AID337523Cytotoxicity against human Col1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID397130Inhibition of phorbol myristate acetate-induced superoxide anion production in mouse peritoneal exudate cells at 50 ug/ml
AID337550Selectivity index, ratio of ED50 for human ZR-75-1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1139785Reduction in membrane fluidity in human MOLT4 cells assessed as fluorescence polarization of DPH by spectrophotofluorometry2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cepharanthine inhibited HIV-1 cell-cell transmission and cell-free infection via modification of cell membrane fluidity.
AID337549Selectivity index, ratio of ED50 for human LNCaP cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1879911Antiviral activity against SARS-CoV-2 infected in African Green monkey Vero cells assessed as inhibition of viral cytopathic effect measured after 72 hrs by inverted microscopic method2022European journal of medicinal chemistry, May-05, Volume: 235Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2.
AID1769489Antiproliferative activity against human HCC1937 assessed as cell growth inhibition after 48 hrs by SRB assay
AID337532Selectivity index, ratio of ED50 for human HT1080 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1139779Cytotoxicity against human MOLT4 cells assessed as cell growth inhibition after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cepharanthine inhibited HIV-1 cell-cell transmission and cell-free infection via modification of cell membrane fluidity.
AID674577Induction of rat C/EBPalpha expression transfected in human U937 cells at 12 uM after 24 hrs by luciferase reporter gene assay relative to ATRA2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID1139783Cytotoxicity against human PHA-blast cells from PBMC assessed as cell growth inhibition at 1 to 10 ug/ml washout after 1 hr measured at 24 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cepharanthine inhibited HIV-1 cell-cell transmission and cell-free infection via modification of cell membrane fluidity.
AID627763Binding affinity to STAT3 G-quadruplex in 3'-flanking region 5'-GGGCTGGGGATGGGGAGGGGG-3' assessed as melting temperature at 10 uM by UV-Vis spectrophotometry (Rvb = 58 degC)2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Formation, recognition and bioactivities of a novel G-quadruplex in the STAT3 gene.
AID337519Cytotoxicity against human BCA1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337518Antimalarial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum W2 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1769497Antiproliferative activity against human HCC70 assessed as cell growth inhibition after 48 hrs by SRB assay
AID745565Cytotoxicity against human HL60 cells after 48 hrs by MTS assay2013Journal of natural products, May-24, Volume: 76, Issue:5
Cytotoxic bisbenzylisoquinoline alkaloids from Stephania epigaea.
AID627762Down regulation of human STAT3 gene expression in human HEK293 cells cloned with MutQ vector harboring G-quadruplex GGG to GTG substitution mutation at 2 to 10 uM after 24 hrs by luciferase reporter gene assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Formation, recognition and bioactivities of a novel G-quadruplex in the STAT3 gene.
AID1769495Antiproliferative activity against human SJRH30 assessed as cell growth inhibition after 48 hrs by SRB assay
AID674572Induction of rat C/EBPalpha expression transfected in human U937 cells after 24 hrs by luciferase reporter gene assay relative to ATRA2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID745564Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay2013Journal of natural products, May-24, Volume: 76, Issue:5
Cytotoxic bisbenzylisoquinoline alkaloids from Stephania epigaea.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID337530Selectivity index, ratio of ED50 for human BCA1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID745562Cytotoxicity against human SW480 cells after 48 hrs by MTS assay2013Journal of natural products, May-24, Volume: 76, Issue:5
Cytotoxic bisbenzylisoquinoline alkaloids from Stephania epigaea.
AID1769494Antiproliferative activity against human A673 assessed as cell growth inhibition after 48 hrs by SRB assay
AID1139790Inhibition of HIV1 envelope Env-dependent cell fusion in JurkatHXBc2 cells expressing Env co-cultured with 1 hr at compound treated PKH67-labelled human MOLT4 cells at 1:1 ratio for 24 hrs by flow cytometry2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cepharanthine inhibited HIV-1 cell-cell transmission and cell-free infection via modification of cell membrane fluidity.
AID337547Selectivity index, ratio of ED50 for human A431 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337534Selectivity index, ratio of ED50 for human LUC1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337533Selectivity index, ratio of ED50 for human HT1080 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1139782Cytotoxicity against human TZM-bl cells assessed as cell growth inhibition at 1 to 10 ug/ml washout after 1 hr measured at 24 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cepharanthine inhibited HIV-1 cell-cell transmission and cell-free infection via modification of cell membrane fluidity.
AID627759Binding affinity to human VEGF G-quadruplex 5'-GGGGCGGGCCGGGGGCGGGG-3' assessed as the intensity ratio of all complex ions to the sum of all G-quadruplex and complex ions at 20 uM by ESI mass spectroscopy relative to control2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Formation, recognition and bioactivities of a novel G-quadruplex in the STAT3 gene.
AID343397Inhibition of Trypanosoma cruzi recombinant trypanothione reductase-substrate complex2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.
AID627754Binding affinity to STAT3 G-quadruplex in 3'-flanking region 5'-GGGCTGGGGATGGGGAGGGGG-3' assessed as intensity ratio of all complex ions to the sum of all G-quadruplex and complex ions at 20 uM by ESI mass spectroscopy relative to control2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Formation, recognition and bioactivities of a novel G-quadruplex in the STAT3 gene.
AID337541Selectivity index, ratio of ED50 for human KB cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337544Selectivity index, ratio of ED50 for mice (Mus musculus) P388 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID627761Down regulation of human STAT3 gene expression in human HEK293 cells cloned with DelQ vector harboring G-quadruplex G-rich sequence deletion at 2 to 10 uM after 24 hrs by luciferase reporter gene assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Formation, recognition and bioactivities of a novel G-quadruplex in the STAT3 gene.
AID337539Selectivity index, ratio of ED50 for human COL1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1139784Cytotoxicity against human PHA-blast cells from CBMC assessed as cell growth inhibition at 1 to 10 ug/ml washout after 1 hr measured at 24 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cepharanthine inhibited HIV-1 cell-cell transmission and cell-free infection via modification of cell membrane fluidity.
AID1139780Cytotoxicity against human MOLT4 cells assessed as cell growth inhibition up to 20 ug/ml washout after 1 hr measured at 24 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cepharanthine inhibited HIV-1 cell-cell transmission and cell-free infection via modification of cell membrane fluidity.
AID1663396Inhibition of P-glycoprotein-mediated Rhodamine-123 efflux in human MOLT4/DNR cells assessed as inhibition of P-glycoprotein efflux function at 1 uM incubated for 1 hr by flow cytometry2020Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12
Bisbenzylisoquinoline alkaloids and P-glycoprotein function: A structure activity relationship study.
AID337522Cytotoxicity against human SK-MEL-2 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID337521Cytotoxicity against human LUC1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID492430Antimalarial activity against Plasmodium falciparum W22009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Antimalarials from nature.
AID337526Cytotoxicity against mouse P388 cells after 2 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337529Cytotoxicity against human ZR-75-1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID627755Binding affinity to STAT3 G-quadruplex in rat cardiomyocytes assessed as down regulation of STAT3 protein expression at 10 uM after 48 hrs by Western blot analysis2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Formation, recognition and bioactivities of a novel G-quadruplex in the STAT3 gene.
AID1171696Inhibition of ABCC10 (unknown origin) assessed as reduction in BeFx-sensitive ATPase activity incubated over 20 mins by inorganic phosphate release assay2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
Synthesis and biological evaluation of pentacyclic strychnos alkaloids as selective modulators of the ABCC10 (MRP7) efflux pump.
AID377946Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-sensitive Plasmodium falciparum D61999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID337542Selectivity index, ratio of ED50 for human KB-V1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337536Selectivity index, ratio of ED50 for human MEL2 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337524Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337527Cytotoxicity against human A431 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1139788Suppression of syncytial formation in HIV1 envelope Env-GFP expressing HEK293T cells co-cultured with 1 hr at up to 5 ug/ml compound treated human TZM-bl cells by fluorescent microscopy2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cepharanthine inhibited HIV-1 cell-cell transmission and cell-free infection via modification of cell membrane fluidity.
AID337545Selectivity index, ratio of ED50 for mice (Mus musculus) P388 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID377945Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes as [3H]hypoxanthine uptake after 24 hrs1999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID1139786Antiviral activity against HIV1 NL4.3 infected in human PHA-blast cells from PBMC assessed as reduction in viral production measured as p24 protein expression cells pretreated for 1 hr with compound at 1 to 5 ug/ml and washed 1 hr after infection measured2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cepharanthine inhibited HIV-1 cell-cell transmission and cell-free infection via modification of cell membrane fluidity.
AID337540Selectivity index, ratio of ED50 for human KB cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337517Antimalarial activity after 24 hrs against chloroquine-sensitive Plasmodium falciparum D6 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337531Selectivity index, ratio of ED50 for human BCA1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1139787Antiviral activity against HIV1 NL4.3 infected in human PHA-blast cells from PBMC assessed as reduction in viral production measured as p24 protein expression cells pretreated for 1 hr with compound at 1 to 5 ug/ml and washed 1 hr after infection measured2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cepharanthine inhibited HIV-1 cell-cell transmission and cell-free infection via modification of cell membrane fluidity.
AID377948Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-sensitive Plasmodium falciparum W21999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID627758Binding affinity to STAT3 G-quadruplex in 3'-flanking region 5'-GGGCTGGGGATGGGGAGGGGG-3' assessed as melting temperature at 40 uM by UV-Vis spectrophotometry (Rvb = 58 degC)2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Formation, recognition and bioactivities of a novel G-quadruplex in the STAT3 gene.
AID1769492Antiproliferative activity against human MDA-MB-453 assessed as cell growth inhibition after 48 hrs by SRB assay
AID337537Selectivity index, ratio of ED50 for human MEL2 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID674579Cytotoxicity against human U937 cells after 24 hrs by alamar blue assay2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID627756Binding affinity to STAT3 G-quadruplex in 3'-flanking region 5'-GGGCTGGGGATGGGGAGGGGG-3' assessed as melting temperature at 20 uM by UV-Vis spectrophotometry (Rvb = 58 degC)2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Formation, recognition and bioactivities of a novel G-quadruplex in the STAT3 gene.
AID1480298Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.
AID745563Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay2013Journal of natural products, May-24, Volume: 76, Issue:5
Cytotoxic bisbenzylisoquinoline alkaloids from Stephania epigaea.
AID674584Cytotoxicity against human U937 cells assessed as cell growth at 12 uM after 24 hrs by alamar blue assay2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID337538Selectivity index, ratio of ED50 for human COL1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID745567Cytotoxicity against human A549 cells after 48 hrs by MTS assay2013Journal of natural products, May-24, Volume: 76, Issue:5
Cytotoxic bisbenzylisoquinoline alkaloids from Stephania epigaea.
AID397131Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced carcinogenic activity in mouse ear at 2 mg, applied locally
AID337543Selectivity index, ratio of ED50 for human KB-V1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337548Selectivity index, ratio of ED50 for human LNCaP cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID627753Binding affinity to STAT3 G-quadruplex in rat cardiomyocytes assessed as down regulation of STAT3 gene expression at 10 uM after 48 hrs by RT-PCR analysis2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Formation, recognition and bioactivities of a novel G-quadruplex in the STAT3 gene.
AID337528Cytotoxicity against human LNCAP cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID377944Cytotoxicity against human KB cells after 72 hrs by SRB assay1999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID1769496Antiproliferative activity against human HCC1806 assessed as cell growth inhibition after 48 hrs by SRB assay
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID337525Cytotoxicity against human KBV1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337546Selectivity index, ratio of ED50 for human A431 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337551Selectivity index, ratio of ED50 for human ZR-75-1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337520Cytotoxicity against human HT1080 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337535Selectivity index, ratio of ED50 for human LUC1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID377947Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected human erythrocytes as [3H]hypoxanthine uptake after 24 hrs1999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID397129Inhibition of phorbol myristate acetate-induced superoxide anion production in mouse peritoneal exudate cells at 5 ug/ml
AID1139781Cytotoxicity against human MOLT4 cells assessed as cell growth inhibition at 1 to 10 ug/ml washout after 1 hr measured at 24 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cepharanthine inhibited HIV-1 cell-cell transmission and cell-free infection via modification of cell membrane fluidity.
AID1139789Inhibition of HIV1 envelope Env-dependent cell fusion in JurkatHXBc2 cells expressing Env co-cultured with 1 hr at compound treated PKH67-labelled human MOLT4 cells at 1:1 ratio for 24 hrs by fluorescent microscopy2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cepharanthine inhibited HIV-1 cell-cell transmission and cell-free infection via modification of cell membrane fluidity.
AID627757Down regulation of human STAT3 gene expression in human HEK293 cells cloned with FRQ vector harboring intact G-quadruplex at 2 to 10 uM after 24 hrs by luciferase reporter gene assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Formation, recognition and bioactivities of a novel G-quadruplex in the STAT3 gene.
AID627760Binding affinity to G-telomeric quadruplex 5'-GGGTTAGGGTTAGGGTTAGGG-3' assessed as the intensity ratio of all complex ions to the sum of all G-quadruplex and complex ions at 20 uM by ESI mass spectroscopy relative to control2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Formation, recognition and bioactivities of a novel G-quadruplex in the STAT3 gene.
AID343384Inhibition of Trypanosoma cruzi recombinant trypanothione reductase2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (322)

TimeframeStudies, This Drug (%)All Drugs %
pre-199071 (22.05)18.7374
1990's72 (22.36)18.2507
2000's53 (16.46)29.6817
2010's78 (24.22)24.3611
2020's48 (14.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.20 (24.57)
Research Supply Index5.85 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index51.24 (26.88)
Search Engine Supply Index1.96 (0.95)

This Compound (36.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (2.06%)5.53%
Reviews17 (5.00%)6.00%
Case Studies9 (2.65%)4.05%
Observational1 (0.29%)0.25%
Other306 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Interventional Efficacy and Safety, Phase 2, Double-blind, 3-arm Study to Investigate Orally Administered High/Low-dose Cepharanthine Compared With Placebo in Nonhospitalized Asymptomatic or Mild Adult Participants With COVID-19 [NCT05398705]Phase 2450 participants (Actual)Interventional2022-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]